产品说明书
Aclacinomycin A
 |
同义名 : | 阿克拉霉素A ;Aclarubicin;NSC 208734;MA 144-A1;Antibiotic MA 144A;Aclucinomycin A;Aclarubicine;Aclacur |
| CAS号 : | 57576-44-0 | |
| 货号 : | A682704 | |
| 分子式 : | C42H53NO15 | |
| 纯度 : | 98+% | |
| 分子量 : | 811.87 | |
| MDL号 : | MFCD00866250 | |
| 存储条件： |
粉末 Keep in dark place,Inert atmosphere,2-8°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 50 mg/mL(61.59 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Aclarubicin is an oligosaccharide anthracycline antineoplastic antibiotic isolated from the bacterium Streptomyces galilaeus. Aclarubicin intercalates into DNA and interacts with topoisomerases I and II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Aclarubicin is antagonistic to other agents that inhibit topoisomerase II, such as etoposide, teniposide and amsacrine. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT03026842 | Acute Myeloid Leukemia | Phase 4 | Active, not recruiting | October 2024 | China, Jilin ... 展开 >> First Hospital of Jilin University Changchun, Jilin, China, 130021 收起 << |
| NCT02432911 | Acute Myeloid Leukemia | Not Applicable | Recruiting | May 2021 | China, Tianjin ... 展开 >> Treatment and Diagnosis Center of Leukemia Recruiting Tianjin, Tianjin, China, 300020 Contact: Jianxiang Wang, MD +862223909120 wangjx@medmail.com.cn Contact: Chunlin Zhou, MD +8613820429085 zcl7317@sina.com 收起 << |
| NCT03560908 | Relapsed AML ... 展开 >>T(8;21) C-KIT Mutation 收起 << | Phase 1 | Recruiting | December 31, 2020 | China, Tianjin ... 展开 >> HBDH Recruiting Tianjin, Tianjin, China, 300020 Contact: Hui Wei 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
1.23mL 0.25mL 0.12mL |
6.16mL 1.23mL 0.62mL |
12.32mL 2.46mL 1.23mL |
| 参考文献 |
|---|